Compare · GH vs MEDS

GH vs MEDS

Side-by-side comparison of Guardant Health Inc. (GH) and DataMeds AI Inc. (MEDS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. GH focuses on Medical Specialities, while MEDS focuses on Other Pharmaceuticals.
  • GH is the larger of the two at $19.49B, about 6285.5x MEDS ($3.1M).
  • GH has been more active in the news (22 items in the past 4 weeks vs 5 for MEDS).
  • GH has more recent analyst coverage (25 ratings vs 1 for MEDS).
MetricGHMEDS
Company
Guardant Health Inc.
DataMeds AI Inc.
Price
-
-
Market cap
$19.49B
$3.1M
1M return
-
-77.82%
1Y return
-
-98.02%
Industry
Medical Specialities
Other Pharmaceuticals
Exchange
NASDAQ
NASDAQ
IPO
2018
News (4w)
22
5
Recent ratings
25
1
GH

Guardant Health Inc.

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

MEDS

DataMeds AI Inc.

DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA -based commercial clinical molecular diagnostics laboratory focused on the ChemoFx Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions.

Latest GH

Latest MEDS